Drug Landscape ›
Feiba VH ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 75
Most-reported reactions
Haemorrhage — 10 reports (13.33%) Myocardial Infarction — 9 reports (12%) Treatment Failure — 9 reports (12%) Drug Ineffective — 8 reports (10.67%) Therapy Non-Responder — 8 reports (10.67%) Factor Viii Inhibition — 7 reports (9.33%) Disseminated Intravascular Coagulation — 6 reports (8%) Pulmonary Embolism — 6 reports (8%) Thrombosis — 6 reports (8%) Vomiting — 6 reports (8%)
Source database →
Feiba VH in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Feiba VH approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Feiba VH in United States?
Novo Nordisk A/S is the originator. The local marketing authorisation holder may differ — check the official source linked above.